NCT01577771View on ClinicalTrials.gov

Immunogenicity and Reactogenicity of PCV13 Among Infants and Children in Burkina Faso

PHASE4CompletedINTERVENTIONAL
Enrollment

663

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Pneumococcal Infections
Interventions
BIOLOGICAL

Prevnar13 (manufactured by Pfizer)

Prevnar13 administered IM in the antero-lateral thigh

Trial Locations (4)

Unknown

CSPS Accart-Ville, Bobo-Dioulasso

Centre Muraz, Bobo-Dioulasso

CSPS Farakan, Bobo-Dioulasso

CSPS Guimbi, Bobo-Dioulasso

All Listed Sponsors
lead

Agence de Médecine Préventive, France

OTHER

NCT01577771 - Immunogenicity and Reactogenicity of PCV13 Among Infants and Children in Burkina Faso | Biotech Hunter | Biotech Hunter